BerGenBio and Oncoinvent to Merge, Creating a Leading Oncology Company with a Focus on Radiopharmaceutical Therapies
[City, State] – June 30, 2025 – BerGenBio ASA, a clinical-stage biopharmaceutical company, and Oncoinvent AS, a pioneering developer of radiopharmaceutical cancer therapies, today announced a significant development in the oncology landscape: a proposed merger that will bring together their complementary strengths and pipelines. This strategic union aims to establish a formidable force in the fight against cancer, with a particular emphasis on leveraging the power of targeted radiotherapies.
The merger, detailed in a press release issued by PR Newswire Healthring, signifies a shared vision to advance innovative treatments for patients battling various forms of cancer. BerGenBio, known for its work in immuno-oncology and its lead candidate bemcentinib, which targets the AXL kinase, will join forces with Oncoinvent, a company at the forefront of developing novel radiopharmaceutical assets. This combination is poised to create a robust pipeline with the potential to address significant unmet medical needs in oncology.
Central to this announcement is also a fully underwritten rights issue, which will provide the necessary financial backing to support the combined entity’s operations and further development of its promising portfolio. This capital infusion will be instrumental in advancing clinical trials, expanding research and development initiatives, and preparing for potential commercialization of their therapeutic candidates.
The proposed merger is expected to yield several key advantages. By integrating BerGenBio’s expertise in immuno-oncology with Oncoinvent’s specialized knowledge in radiopharmaceuticals, the new company will possess a broader therapeutic platform. This diversification is anticipated to enhance the ability to identify and develop synergistic treatment approaches, potentially leading to more effective and personalized cancer therapies. Radiopharmaceuticals, which deliver targeted radiation directly to cancer cells, represent a rapidly evolving and highly promising area of cancer treatment, and Oncoinvent’s innovative approach in this field is particularly noteworthy.
While the specifics of the merged entity’s leadership and operational structure will be subject to further details and regulatory approvals, the announcement signals a strong commitment to advancing a shared mission. Both companies have demonstrated dedication to scientific rigor and patient-centric drug development, values that will undoubtedly guide the newly formed organization.
The proposed merger is anticipated to be structured as a stock-for-stock transaction, subject to customary closing conditions, including shareholder approvals from both BerGenBio and Oncoinvent, as well as regulatory clearances. The rights issue will also be structured to ensure broad participation and provide a solid financial foundation for the future.
This strategic alignment represents a significant step forward in the ongoing efforts to combat cancer. By joining forces, BerGenBio and Oncoinvent are positioning themselves to make a substantial impact on the lives of patients worldwide, offering new hope through innovative and targeted therapeutic solutions. Further updates regarding the merger and rights issue are expected as the process progresses.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue’ at 2025-06-30 20:31. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.